Exciting moment for VICO to present our first clinical data with VO659 in Huntington's Disease patients today at the European Huntington's Disease Network conference!
Today at the European Huntington's Disease Network (EHDN)’s EHDN & Enroll-HD 2024 meeting, we announced new interim data from our ongoing Phase 1/2a clinical study, including a safety, tolerability, and biomarker analysis for participants with Huntington’s disease. This study is part of our broader research into therapies targeting diseases caused by CAG repeat expansions, and we look forward to advancing the program and discussing future steps with regulators later this year. See our press release for more information: https://lnkd.in/e9hxmhV5 #EHDN2024 #EnrollHD2024 #HuntingtonsDisease #SpinocerebellarAtaxia #Neurology #ClinicalResearch #NeurodegenerativeDiseases #ClinicalTrials